rIL-2 has often been tried to treat different types of cancers. Tumor responses were observed mainly in patients with melanoma and renal cell carcinoma.2Kojima et al mentioned the study of Masuzawa et al3and wrote that the “systemic administration of high doses of rIL-2 was also highly effective and induced the regression of pulmonary metastasis,” but these conclusions are drawn from mice only. In human AS, rIL-2 therapy was almost always used with RX or chemotherapy, and, therefore, the potential efficacy of rIL-2 by itself cannot be assessed in AS, since it is also known to be a radiosensitive tumor. Of notice, in the retrospective study (30 patients) performed by Sasaki et al,4and referenced by Kojima et al, the four long-term survivors (ie, > 3 years) were patients with nonmetastatic AS who had been treated with rIL-2 but also with curative RX. Finally, several chemotherapeutic drugs were tested in patients with AS. A few of them showed promising activity, except for paclitaxel in skin (ie, face and scalp) ASs.5 This drug gave interesting results (eight partial and complete responses among nine patients) when used alone without RX, unlike the case with rIL-2. In our opinion, rIL-2 may be valuable in the treatment of patients with AS, but its efficacy should first be evaluated as a single agent before using it in association with RX. Moreover, one should be cautious with rIL-2 because of its potential toxicity, especially at high dosages.